A randomised phase II study of conventional versus accelerated infusional chemotherapy with granulocyte colony-stimulating factor support in advanced breast cancer

Annals of Oncology

Volumn 13, Issue 6, 2002, Pages 889-894

  De Boer, R H ^a   Eisen, T G ^a   Ellis, P A ^b   Johnston, S R D ^a   Walsh, G ^a   Ashley, S ^a   Smith, I E ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b Guys and St Thomasas NHS Trust   (United Kingdom)

Author keywords

5 fluorouracil; Accelerated; Breast cancer; Cyclophosphamide; Epirubicin; Granulocyte colony stimulating factor

Indexed keywords

ANTIBIOTIC AGENT; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOMPERIDONE; EPIRUBICIN; FLUOROURACIL; GRANISETRON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; ONDANSETRON; PYRIDOXINE; TAMOXIFEN; WARFARIN; ANTINEOPLASTIC AGENT;

ADULT; ALOPECIA; ARTICLE; BOLUS INJECTION; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CHEMOTHERAPY; CELL CYCLE S PHASE; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE EXACERBATION; DRUG ACTIVITY; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; DRUG TOLERABILITY; HAND FOOT SYNDROME; HOT FLUSH; HUMAN; INFECTION; LETHARGY; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; NEUTROPENIA; NEUTROPHIL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; STOMATITIS; THROMBOCYTE; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; CANCER STAGING; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECT; FEMALE; FOLLOW UP; HEMATOPOIESIS; INTRAVENOUS DRUG ADMINISTRATION; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MORTALITY; NEEDLE BIOPSY; PATHOLOGY; REFERENCE VALUE; SURVIVAL; TREATMENT OUTCOME; UNITED KINGDOM;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY, NEEDLE; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMPARATIVE STUDY; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EPIRUBICIN; FEMALE; FOLLOW-UP STUDIES; GRANULOCYTE COLONY-STIMULATING FACTOR; GREAT BRITAIN; HEMATOPOIESIS; HUMAN; INFUSIONS, INTRAVENOUS; MAXIMUM TOLERATED DOSE; MIDDLE AGE; NEOPLASM STAGING; REFERENCE VALUES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; HUMANS; MIDDLE AGED;

EID: 0035990074     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdf150     Document Type: Article

References (22)

1. Granulocyte-macrophage colony-stimulating factor (GM-CSF) allows acceleration and dose-intensity increase of CEF chemotherapy: A randomised study in patients with advanced breast cancer
2. Phase I study of accelerated FEC with granulocyte colony-stimulating factor (Lenograstim) support
3. An EORTC pilot study of filgrastim (recombinant human granulocyte colony stimulating factor) as support to a high dose-intensive epiadriamycin-cyclophosphamide regimen in chemotherapy-naïve patients metastatic breast cancer
4. Accelerated chemotherapy with high-dose epirubicin and cyclophosphamide plus r-met-HUG-CSF in locally advanced and metastatic breast cancer
5. Comparative study of dose escalation versus interval reduction to obtain dose-intensification of epirubicin and cyclophosphamide with granulocyte colony-stimulating factor in advanced breast cancer
6. Phase II study of epirubicin and vinorelbine with granulocyte colony-stimulating factor: A high-activity, dose-dense weekly regimen for advanced breast cancer
7. High-dose epirubicin and cyclophosphamide every two weeks as first-line chemotherapy for relapsing metastatic breast cancer patients
8. A pilot study of accelerated cyclophosphamide, epirubicin and 5-fluorouracil plus granulocyte colony stimulating factor as adjuvant therapy in early breast cancer
9. Neoadjuvant chemotherapy with accelerated CNF plus G-CSF in patients with breast cancer tumours larger than three centimetres: A pilot study
10. Dose-dense adjuvant chemotherapy with epirubicin monotherapy in patients with operable breast cancer and ≥10 positive axillary lymph nodes. A feasibility study
11. Phase II study of continuous infusional 5-FU with epirubicin and cisplatin (infusional ECF) in patients with metastatic and locally advanced breast cancer: An active new regimen
12. Continuous infusional combination chemotherapy in inflammatory breast cancer: A phase II study
13. High complete remission rates with primary neoadjuvant chemotherapy for large early breast cancer
14. Biology of G-CSF
15. Adverse effect on bone marrow protection of pre-chemotherapy granulocyte colony-stimulating factor support
16. Reporting results of cancer treatment
17. One sample multiple testing procedure for phase II clinical trials
18. Accelerated chemotherapy (CT) with two schedules of granulocyte colony-stimulating factor (G-CSF) in advanced breast cancer
19. Phase I/II clinical trial of epirubicin and paclitaxel followed by granulocyte colony-stimulating factor in a 2-week schedule in patients with advanced or metastatic breast cancer
20. Dose intensification of epidoxorubicin and cyclophosphamide in metastatic breast cancer: A randomised study with two schedules of granulocyte-macrophage colony stimulating factor
21. Low-dose fluorouracil with eniluracil as first-line chemotherapy against advanced breast cancer: A phase II study
22. Multicentre phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer